Published · Aurelis Peptides
Tesamorelin and sermorelin share a starting point: both are related to growth-hormone-releasing hormone, usually shortened to GHRH. This signal encourages the pituitary gland to release growth hormone. The key difference in this comparison is what the studies measured: abdominal fat for tesamorelin, and the immediate growth-hormone response for sermorelin.
Those findings help explain interest in the two names. They also give you a clearer way to compare a research paper with a catalogue entry. Start with the table, then keep the study population and endpoint beside every result.
Tesamorelin vs sermorelin at a glance
| Compare | Tesamorelin | Sermorelin |
|---|---|---|
| GHRH relationship | Modified 44-amino-acid GHRH analogue | 29-amino-acid GHRH fragment, with an amide end group |
| Selected human studies here | 2007 and 2010 trials in adults with HIV and excess abdominal fat | 1984 comparison in five healthy volunteers |
| Main measurement | Change in visceral abdominal fat | Growth-hormone levels in blood |
| Aurelis catalogue content | 5 mg / 10 mg per unit | 10 mg per unit |
Same hormone family, different peptide identities
Tesamorelin is based on GHRH’s 44-amino-acid sequence, with a modification at one end. Sermorelin corresponds to the first 29 amino acids of GHRH, with an amide end group. Amino acids are the building blocks in a peptide chain.
The shorter and longer sequences identify different materials. Chain length alone does not rank their effects. The shared releasing-hormone background explains why both appear in growth-hormone discussions; the trials tell you which changes researchers actually measured. Tesamorelin identity in the primary trial · NCBI’s sermorelin definition.
Tesamorelin: abdominal-fat findings
The 2007 Falutz trial enrolled 412 adults with HIV and accumulated abdominal fat. Its primary endpoint was the percentage change in visceral fat over 26 weeks, measured using CT scans. Visceral fat is fat around internal organs; it is different from the fat directly beneath the skin.
Visceral fat decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group. That is a change in the measured fat compartment, rather than a percentage of total body weight lost. The paper also reported more withdrawals because of adverse events in the tesamorelin group. Read Falutz et al., 2007.
A separate 2010 trial enrolled 404 adults with HIV and excess abdominal fat in the setting of antiretroviral therapy. At six months, visceral fat decreased by 10.9% with tesamorelin, versus 0.6% with placebo. The extension phase examined what happened when participants continued tesamorelin or switched to placebo; the initial visceral-fat improvement was rapidly lost in those who switched. Read the 2010 trial and extension.
These are findings in defined HIV-associated populations. They do not establish a general weight-loss result for everyone, or a result for an Aurelis catalogue material. For the individual topic, read our tesamorelin abdominal-fat guide.
Sermorelin: the growth-hormone response
Losa and colleagues compared GHRH peptides with 44, 40 and 29 amino acids in five healthy volunteers in 1984. They measured growth-hormone levels in blood and compared the response with placebo.
All three peptide lengths produced a significant rise in growth hormone. The largest rises did not differ significantly between the lengths in this small study. The 29-amino-acid form is relevant to sermorelin. Read Losa et al., 1984.
The finding concerns a hormone response. This experiment did not measure long-term weight loss, muscle gain or changes in ageing. A blood-hormone measurement and a CT-measured fat change are different endpoints. Our sermorelin growth-hormone guide explores the releasing signal in more detail.
How to read the comparison
Use the research question to organise the evidence. For tesamorelin’s abdominal-fat findings, note the HIV-associated population, the fat compartment and the months of follow-up. For sermorelin’s selected study, note the five healthy volunteers and the immediate blood-hormone response.
These papers studied different populations and endpoints. They are not a direct tesamorelin-versus-sermorelin trial. A stronger hormone response cannot be assumed to mean a larger fat reduction, and a fat-compartment result cannot be converted into total weight loss.
Tesamorelin 5 mg or 10 mg; sermorelin 10 mg
Aurelis lists tesamorelin 5 mg / 10 mg and sermorelin 10 mg per unit. These numbers describe catalogue content. They are not doses, concentrations or measures of biological activity.
When comparing entries, keep the compound name attached to the amount. A 10 mg listing for each peptide does not make them interchangeable. Request the identity and content records for the exact selected entry; a purity percentage alone answers a different question from the amount present.
Prepare a useful vial or kit enquiry
Aurelis presents both vials and pen-style kits. Confirm the available format and complete packaging for the specific peptide and listed content. A presentation image does not establish every component or specification for every catalogue item.
Include the compound, content option, preferred presentation and destination in Australia, Canada or the USA. Ask for matching batch documents and confirmation of local availability. The vial and kit guide and quality documentation guide help structure the enquiry.
Send a tesamorelin or sermorelin enquiry, or email sales@aurelispeptides.com.
Primary research and identity sources
- Falutz et al. · New England Journal of Medicine · 2007 — 412 adults with HIV, CT-measured visceral-fat endpoint at 26 weeks, and tesamorelin identity.
- Falutz et al. · Journal of Acquired Immune Deficiency Syndromes · 2010 — 404 adults with HIV, six-month efficacy phase and continuation/switch extension.
- Losa et al. · Klinische Wochenschrift · 1984 — three GHRH peptide lengths, five healthy volunteers and blood growth-hormone response.
- NCBI MeSH · Sermorelin — identity of the GHRH(1–29)-amide fragment.